Nextleaf Solutions will look to commercialize new patent for acetylation of cannabinoids

The US Patent and Trademark Office has awarded the firm a patent for a process called the acetylation of cannabinoids

Nextleaf's patented process produces THC-O-Acetate, a cannabinoid-derived metabolic prodrug, the firm said

Nextleaf Solutions Ltd (CSE:OILS) (OTCMKTS:OILFF) revealed it had bolstered its IP (intellectual property) with a new patent covering a cannabinoid-derived prodrug, which could have unique medicinal benefits.

The US Patent and Trademark Office has awarded the firm a patent for a process called the acetylation of cannabinoids.

READ: Nextleaf Solutions continues success streak with thirteenth patent

"Nextleaf's patented process produces THC-O-Acetate, a cannabinoid-derived metabolic prodrug with potentially very unique medicinal benefits associated with efficient and targeted drug delivery," said Ryan Ko, the group's chief technology officer.

Put simply, a prodrug is a biologically inactive compound that can be metabolized in the body to produce an active drug. Prodrugs use various physical and chemical modifications to improve the features of active drugs.

"Anecdotal accounts have reported gradual onset, longer-lasting benefits, and altered psychological effects when compared to THC," added Ko.

Nextleaf expects opportunities to commercialize this patent through IP licensing to pharmaceutical companies, or producing IP protected cannabinoid products where legal jurisdictions allow, it said in a statement.

Revenue from royalties

The firm began making revenue in December 2019 from royalties earned on its patent portfolio.

"With this new U.S. patent, we are able to efficiently modify and potentially improve upon the medicinal properties of a natural product that has been in use for thousands of years," said Paul Pedersen, Nextleaf's CEO.

"As large pharmaceutical companies look to enter this space we believe such IP protected processes and resulting products will draw a lot of attention."

Nextleaf owns a portfolio of 14 issued patents and over 60 pending patents for the extraction, purification, and formulation of cannabinoids.

Contact the author at [email protected]


Price: 0.265 CAD

Market: CSE
Market Cap: $28.9 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of NEXTLEAF SOLUTIONS Ltd. named herein, including the promotion by the Company of NEXTLEAF SOLUTIONS Ltd. in any Content on the Site, the Company...



Nextleaf Thought Leadership Series– "The state of IP in the cannabis...

Nextleaf Solutions (CSE: OILS-OTCQB: OILFF) CEO Paul Pedersen joined Steve Darling from Proactive Vancouver to discuss why the company has made it part of their mandate to protect their Intellectual Property with the issuance of patents. Pedersen also shared his thoughts about the cannabis...

2 weeks, 6 days ago

2 min read